Share General Information
Crisaborole is a small-molecule compound, non-steroidal and anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor used for the treatment of mild-to-moderate atopic dermatitis (eczema) in adults and children (at the age of 2 and older). PDE4 is an enzyme that converts the intracellular second messenger 3’5′-cyclic adenosine monophosphate (cAMP) into the active metabolite adenosine monophosphate (AMP). By inhibiting PDE4 and thus increasing levels of cAMP, crisaborole controls inflammation. The use of boron chemistry enabled synthesis of a low-molecular-weight compound (251 daltons), thereby facilitating effective penetration of crisaborole through human skin.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
